Nutrafol Women Review: The Trials, and Who Wrote Them

Nutrafol is the hair supplement women are most likely to be shown, and it is also the one with the most to review — because unlike most of its category, it has randomised, double-blind, placebo-controlled trials behind it, published in a peer-reviewed dermatology journal, with the product named in the paper.

It also has the problem that makes this review necessary: those trials were funded by the company and co-authored by one of its co-founders. Both of those facts are true at once, and a useful review has to hold them together rather than pick the convenient one.

What Nutrafol actually sells to women

Three core formulas, each four capsules a day, each aimed at a different group: Nutrafol Women for ages 18 to 44, Women's Balance for 45 and over, and Postpartum for the first year after childbirth. The company describes results in three to six months, with reduced shedding possible in the first one to three, and attaches a money-back offer it calls a growth guarantee to the longer subscriptions.

Everything in this review is read from the company's own pages on 24 September 2026, from its trial papers on PubMed, and from the FDA's published position on supplements. Nothing here was tested by us — we treat nobody and measure nothing — and a product page is the right place to read the current label before buying: Nutrafol's own site carries both.

Three formulas, one price

The three women's formulas cost exactly the same: $88 bought one month at a time, $79 a month on the monthly plan, $224 on the three-month plan or $422 on the six-month plan, with free shipping and cancellation described as available at any time.

That sameness is worth a moment. The formulas differ in composition and in who they are marketed to, and a company is entitled to price a range flat. But it does mean the price you pay is not telling you anything about how much evidence sits behind the specific formula you were sold — and as the next section shows, that varies a great deal.

The trials behind it, and who wrote them

Two randomised, double-blind, placebo-controlled trials in women exist, and they are easy to check.

The first, published in the Journal of Drugs in Dermatology in 2018, randomised 40 adult women with self-perceived thinning — 26 on the supplement, 14 on placebo — over six months. It reported a significant increase in terminal and vellus hairs in the target area at day 90 and day 180 versus placebo (P < 0.009), significant improvements in blinded investigator global assessments of growth and quality, and no reported adverse events.

The second, published in the same journal in January 2021, covered Women's Balance: 70 perimenopausal, menopausal and postmenopausal women with self-perceived thinning — 40 on the supplement, 30 on placebo — again over six months. It reported progressive, significant increases in terminal and total hair counts at day 90 and day 180 (P < 0.01), and hair shedding down by 32.41% against placebo by day 180.

Both papers list the same two authors, Ablon G and Kogan S. Nutrafol's own "Our Story" page names Dr Sophia Kogan, M.D. among the company's three co-founders. That is not an accusation of fraud — company-sponsored trials are legal, common and often the only trials that get funded — but it is the reason no serious reader treats a single company-authored study as settled. The thing that would settle it is independent replication, and on the evidence we could find, that has not happened.

How this site scored it

This site scores products out of ten on a published scale: three points for a randomised controlled trial in women, three for who funded and wrote it, two for putting the price and the exit in the open, and two for stating the real cautions where a buyer will see them. Nutrafol's women's range scores 6 out of 10.

It takes the full three for trials in women, because they exist, are randomised, placebo-controlled and published. It takes zero for independence, because both were funded by the company and co-authored by a co-founder. It takes the full two for price transparency, because the prices, the cadence and the cancellation terms are all readable before you give anyone an email address. It takes one of two for cautions: the postpartum page does say to check with your doctor before starting any supplement, but the percentages sitting above that sentence are the company's own uncontrolled figures, presented as results.

Anyone who thinks the funding mark is too harsh, or the caution mark too generous, can move it: the scale is published precisely so it can be argued with.

The postpartum formula is a different proposition

The postpartum product is the one to look hardest at, because the condition it addresses usually resolves without it. Dermatologists' own guidance is that shedding after a birth peaks around four months and that most women regain normal growth by their child's first birthday.

The page for that formula cites a six-month study in which 91% of users saw less shedding after two months, 91% saw improvement in their hairline after four months and 100% saw visibly thicker hair after six. Those are the company's figures, and no published, placebo-controlled trial of a postpartum hair supplement turned up in a PubMed search on 24 September 2026. A product taken across the exact months in which the condition naturally resolves cannot be distinguished from the resolution without a control group.

The safety wording deserves reading closely too: the company says the ingredients are used within FDA-set doses for postpartum women with none found to be contraindicated in breastfeeding, and that you should check with your doctor before starting any supplement. That is a statement about ingredient lists, not a regulatory approval, and the second half of it is the part to act on. What actually happens in postpartum shedding, and when is the context that makes the decision easier.

What it is not

It is not a medicine, and the company does not claim it is. Dietary supplements are not approved by the FDA before they are sold — the agency's own consumer Q&A says it has no authority to approve them, and that responsibility for a product being neither adulterated nor misbranded rests with the firm selling it. Nothing in this category can treat female pattern hair loss in the way an approved drug is judged to.

It is also not a diagnosis. If the thinning is a widening part, a shedding phase, traction, thyroid disease or iron deficiency, the supplement does not distinguish between them and neither does the questionnaire that sold it to you. That is what every hair-loss treatment for women, graded by what was tested in women is for: it puts this product exactly where its evidence puts it, below the routes with independent trials and above the ones with none.

Who might reasonably buy it

Someone whose diagnosis is established, who is already doing whatever the diagnosis calls for, who has spare money, and who would rather take the best-studied thing in a weakly studied category than the cheapest thing in it. That is a real person and it is a defensible purchase.

Someone who has not yet been examined, or who is buying it instead of finding out what is going on, is buying the wrong thing at $1,056 a year — and that is the only sentence in this review that we would keep if we had to delete all the others.